Implementation of A Universal Analytical Method in Early-Stage Development of Human Antibody Therapeutics: Application to Pharmacokinetic Assessment For Candidate Selection

Judy Shih, Vimal Patel, Andrew D. Watson, Todd Hager, Peng Luan, Hossein Salimi-Moosavi, Mark Ma

Bioanalysis · 2012 · 17 citations · 8 references

Concepts

Abstract

BACKGROUND: Effective bioanalytical support for pharmacokinetic assessment of therapeutics in early development remains challenging. Concurrent evaluation of multiple candidates per program is typical, requiring efficient characterization in various preclinical species; an ambitious effort often complicated by assay reagent unavailability and limited sample volume. Accordingly, a universal anti-human Fc assay for human monoclonal antibody and derived therapeutics was developed using a microfluidics platform to address these bioanalytical challenges. RESULTS: The universal assay with standardized format was qualified for quantitation of human IgG Fc-containing biotherapeutics in matrices from commonly used preclinical species. Results from this assay compared well with those from traditional colorimetric immunoassays. Furthermore, result comparison between the universal and target-specific assays provided additional information on the effect of antidrug antibodies and in vivo drug catabolism. CONCLUSION: This assay has wide applicability as a default bioanalytical approach in therapeutic candidate selection and preliminary pharmacokinetics evaluation during early-stage therapeutic development.

References

8